BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$82.10 USD
-0.34 (-0.41%)
Updated May 6, 2024 04:00 PM ET
After-Market: $82.10 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth C Momentum D VGM
Brokerage Reports
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 81 - 100 ( 812 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
European Commission Grants CMA to ROCTAVIAN; EU Launch Expected in Q4:22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q2: Another VOXZOGO Beat & Raise; Focus Remains on ROCTAVIAN Regulatory Path
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
ISTH 2022: Further Insight into ROCTAVIAN Ahead of Potential EU Approval in Q3
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
CHMP Recommends CMA for ROCTAVIAN; Focus Turns to Commercial Opportunity
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
E.N.D.O - Exploring New Drug Opportunities in Endocrinology KOL Call Highlights
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
VOXZOGO Launch & ROCTAVIAN Approvals Key to Growth; Assuming at NEUTRAL, $70 PT
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Ph1/2 Data Continues to Show ROCTAVIAN''s Long-Term Benefit; BLA Timeline Update
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: Research Department